Mobile

A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-005173-20

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP (non-activated B-cell) or R2-CHOP (activated B-cell) followed by durvalumab consolidation therapy in previously untreated subjects diagnosed with high-risk DLBCL.

Critère d'inclusion

  • Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)

Liens